Intuitive Surgical, Inc. $ISRG Stock: Assenagon Asset Management S.A. Raises Position

Key Points

• Assenagon Asset Management increased its Intuitive Surgical stake by 55.8% in the third quarter, bringing its holdings to 1.56 million shares worth approximately $633.5 million. Institutional investors collectively own 83.64% of the company.
• Insiders sold 12,370 shares worth about $4.9 million during the latest quarter, including sales by executives Mark Brosius and Gary Loeb under pre-arranged Rule 10b5-1 plans.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and an average price target of $498.83. However, Intuitive Surgical trades at an elevated valuation of roughly 50 times earnings, despite recently beating quarterly estimates with 18.4% year-over-year revenue growth.

Assenagon Asset Management S.A. raised its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 55.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,557,940 shares of the medical equipment provider's stock after purchasing an additional 558,099 shares during the period. Assenagon Asset Management S.A. owned 0.44% of Intuitive Surgical worth $633,505,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of ISRG. Bank of New York Mellon Corp bought a new position in Intuitive Surgical during the second quarter valued at $1,335,753,000. Arrowstreet Capital Limited Partnership raised its stake in shares of Intuitive Surgical by 95.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider's stock valued at $970,635,000 after acquiring an additional 1,027,475 shares during the period. Invesco Ltd. lifted its holdings in shares of Intuitive Surgical by 17.4% in the 4th quarter. Invesco Ltd. now owns 4,128,735 shares of the medical equipment provider's stock worth $2,338,350,000 after acquiring an additional 611,268 shares during the last quarter. Capitolis Liquid Global Markets LLC lifted its holdings in shares of Intuitive Surgical by 1,070.2% in the 4th quarter. Capitolis Liquid Global Markets LLC now owns 503,171 shares of the medical equipment provider's stock worth $284,976,000 after acquiring an additional 460,171 shares during the last quarter. Finally, Employees Provident Fund Board bought a new stake in shares of Intuitive Surgical in the 4th quarter worth about $248,368,000. 83.64% of the stock is owned by institutional investors.

Insider Buying and Selling at Intuitive Surgical

In other news, EVP Mark Brosius sold 77 shares of the firm's stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $375.57, for a total transaction of $28,918.89. Following the transaction, the executive vice president directly owned 881 shares of the company's stock, valued at approximately $330,877.17. This trade represents a 8.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of Intuitive Surgical stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $379.00, for a total transaction of $151,600.00. Following the sale, the executive vice president directly owned 5,320 shares of the company's stock, valued at $2,016,280. This represents a 6.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 12,370 shares of company stock valued at $4,891,989. 0.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ISRG shares. Wells Fargo & Company reiterated an "overweight" rating and set a $487.00 price target (down from $654.00) on shares of Intuitive Surgical in a report on Friday, July 17th. JPMorgan Chase & Co. decreased their price objective on shares of Intuitive Surgical from $550.00 to $450.00 and set an "overweight" rating for the company in a research note on Friday, July 17th. TD Cowen downgraded shares of Intuitive Surgical from a "buy" rating to a "hold" rating in a research note on Tuesday, July 28th. BNP Paribas Exane upgraded Intuitive Surgical to an "outperform" rating in a research report on Tuesday, July 28th. Finally, Royal Bank Of Canada dropped their target price on Intuitive Surgical from $650.00 to $600.00 and set an "outperform" rating for the company in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $498.83.

Intuitive Surgical News Roundup

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive Surgical outperformed the broader market in the latest session, supported by its long-term growth profile and investor interest ahead of earnings. The company’s most recent quarterly results also showed strong momentum, with earnings and revenue exceeding analyst expectations and revenue rising 18.4% year over year. Intuitive Surgical Beats Stock Market Upswing
• Positive Sentiment: Analysts are watching da Vinci 5 adoption, Ion procedures, surgical-system placements and recurring instrument and accessory revenue as potential indicators of another strong quarter. These operating metrics could provide more insight than revenue and earnings per share alone. Countdown to Intuitive Surgical Q3 Earnings
• Positive Sentiment: Erste Group Bank marginally raised its fiscal 2026 earnings forecast to $8.94 per share, above the approximately $8.87 consensus estimate, signaling modestly improved expectations for profitability.
• Neutral Sentiment: Intuitive Surgical has gained nearly 12% over the past month, making the upcoming earnings release an important catalyst for whether the recent rally can continue. Analysts also highlight the company as a sales-growth stock, with strong projected revenue expansion for 2026. ISRG Gains Nearly 12% in a Month
• Negative Sentiment: Valuation remains a concern: ISRG trades at roughly 49 times earnings, and one analysis estimates the shares could be about 31% overvalued even after an improved earnings outlook. Any weaker-than-expected Q3 metrics or cautious guidance could pressure the stock. Intuitive Surgical Could Be 31% Overvalued

Intuitive Surgical Trading Up 1.8%

NASDAQ ISRG opened at $427.86 on Friday. The stock has a market cap of $151.15 billion, a PE ratio of 50.33, a PEG ratio of 3.17 and a beta of 1.46. Intuitive Surgical, Inc. has a 12 month low of $328.57 and a 12 month high of $603.88. The company's 50-day moving average price is $390.47 and its 200-day moving average price is $409.62.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings data on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share for the quarter, beating analysts' consensus estimates of $2.48 by $0.32. The company had revenue of $2.89 billion during the quarter, compared to analyst estimates of $2.83 billion. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The firm's revenue for the quarter was up 18.4% on a year-over-year basis. During the same quarter last year, the business posted $1.81 EPS. As a group, sell-side analysts forecast that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops and commercializes robotic-assisted systems and related technologies designed to support minimally invasive medical procedures. The company's products are intended to help surgeons perform operations through small incisions while providing enhanced visualization, precision, and control.

Its principal product is the da Vinci Surgical System, a platform used across a range of specialties, including general surgery, urology, gynecology, thoracic surgery, and cardiac procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.